Literature DB >> 15545129

Reliability of exophthalmos measurement and the exophthalmometry value distribution in a healthy Dutch population and in Graves' patients. An exploratory study.

M P Mourits1, S H C Lombardo, F A van der Sluijs, S Fenton.   

Abstract

AIM: The purpose of this study was to test the reliability of an exophthalmometer commonly used in the Netherlands; to determine the exophthalmometry value distribution with this instrument and to assess the upper exophthalmometry limits of normal in a healthy, adult, Caucasian, Dutch population. Furthermore, to assess the effects of gender and age on exophthalmometry readings in this group and in a group of Graves' patients by comparing healthy, adult, Caucasian, Dutch individuals with adult, Caucasian, Dutch Graves' patients.
METHODS: To test the reliability of our Hertel exophthalmometer, we determined the interobserver variation between two observers by measuring 160 eyes in healthy, adult, Caucasian, Dutch females and males (10 females and 10 males in each decade between 20 and 60 years of age). These data were also used for the assessment of the Hertel value distribution and for defining the upper limits of normal in these individuals by logistic regression analysis. The effects of disease, age and gender were established using these data plus data of a retrospective study of 393 adult, Caucasian, Dutch females (n=294) and males (n=99) with Graves' orbitopathy in whom Hertel values were measured with the same exophthalmometer.
RESULTS: Exophthalmometry using an Hertel exophthalmometer appeared reliable (Pearson correlation coefficient for interobserver variation 0.89; 96% of the Hertel values measured by two observers were within the limits (of 2 mm) of agreement). Hertel values usually show a normal distribution in healthy individuals and in Graves' patients and are sex- and age-dependent, but there was no dependence on age in this small series in adults. Logistic regression analysis revealed an upper limit of normal of 16 mm in females and 20 mm in males in our group, using the exophthalmometer described.
CONCLUSIONS: Exophthalmometry is reliable and absolute measurement of proptosis is feasible. International standardization of Hertel exophthalmometry is required in order to compare exophthalmometry data in the literature reliably.

Entities:  

Mesh:

Year:  2004        PMID: 15545129     DOI: 10.1080/01676830490504089

Source DB:  PubMed          Journal:  Orbit        ISSN: 0167-6830


  21 in total

1.  Imaging biomarkers in thyroid eye disease and their clinical associations.

Authors:  Shikha Chaganti; Katrina Nelson; Kevin Mundy; Robert Harrigan; Robert Galloway; Louise A Mawn; Bennett Landman
Journal:  J Med Imaging (Bellingham)       Date:  2018-10-16

2.  Relationship between serum cholesterol and Graves' orbitopathy (GO): a confirmatory study.

Authors:  G Lanzolla; E Sabini; M A Profilo; B Mazzi; A Sframeli; R Rocchi; F Menconi; M Leo; M Nardi; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2018-06-19       Impact factor: 4.256

3.  Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey.

Authors:  David McKeag; Carol Lane; John H Lazarus; Lelio Baldeschi; Kostas Boboridis; A Jane Dickinson; A Iain Hullo; George Kahaly; Gerry Krassas; Claudio Marcocci; Michele Marinò; Maarten P Mourits; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Petros Perros; Aldo Pinchera; Susanne Pitz; Mark F Prummel; Maria S Sartini; Wilmar M Wiersinga
Journal:  Br J Ophthalmol       Date:  2006-10-11       Impact factor: 4.638

4.  Regression of Ophthalmopathic Exophthalmos in Graves' Disease After Total Thyroidectomy: a Prospective Study of a Surgical Series.

Authors:  P R K Bhargav; M Sabaretnam; S Chandra Kumar; S Zwalitha; N Vimala Devi
Journal:  Indian J Surg       Date:  2016-06-22       Impact factor: 0.656

5.  Risk factors associated with the severity of thyroid-associated orbitopathy in Korean patients.

Authors:  Ji Hwan Lee; Sang Yeul Lee; Jin Sook Yoon
Journal:  Korean J Ophthalmol       Date:  2010-10-05

6.  Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question.

Authors:  Elena Sabini; Marenza Leo; Barbara Mazzi; Roberto Rocchi; Francesco Latrofa; Marco Nardi; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Eur Thyroid J       Date:  2017-06-26

7.  Functional outcome measures for NF1-associated optic pathway glioma clinical trials.

Authors:  Michael J Fisher; Robert A Avery; Jeffrey C Allen; Simone L Ardern-Holmes; Larissa T Bilaniuk; Rosalie E Ferner; David H Gutmann; Robert Listernick; Staci Martin; Nicole J Ullrich; Grant T Liu
Journal:  Neurology       Date:  2013-11-19       Impact factor: 9.910

8.  Occurrence of Graves' Orbitopathy and Graves' Hyperthyroidism after a Trauma to the Eye.

Authors:  Elena Sabini; Ilaria Ionni; Roberto Rocchi; Paolo Vitti; Claudio Marcocci; Michele Marinò
Journal:  Eur Thyroid J       Date:  2017-08-22

9.  Planning health care for patients with Graves' orbitopathy.

Authors:  Inna V Sasim; Tos T J M Berendschot; Chantal van Isterdael; Maarten P Mourits
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-06-26       Impact factor: 3.117

10.  Unilateral proptosis in thyroid eye disease with subsequent contralateral involvement: retrospective follow-up study.

Authors:  Diego Strianese; Raffaele Piscopo; Andrea Elefante; Manuela Napoli; Chiara Comune; Immacolata Baronissi; Raffaele Liuzzi; Mariantonia Ferrara; Alessia D'alessandro; Pasquale Ruggiero; Pasquale Napolitano; Piergiacomo Grassi; Adriana Iuliano; Carmela Russo; Arturo Brunetti; Giulio Bonavolontà
Journal:  BMC Ophthalmol       Date:  2013-05-30       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.